Teri L. Lawver - 01 May 2026 Form 4 Insider Report for Altimmune, Inc. (ALT)

Reporting relationship: Director
Issuer ticker: ALT
Reported as of: 01 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 May 2026, 16:23:16 UTC
Prior SEC filing: 12 Nov 2025
Next SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Gregory Weaver, as Attorney-in-Fact

Key filing fact

Teri L. Lawver filed Form 4 for Altimmune, Inc. (ALT) on 01 May 2026.

Key facts

This page summarizes Teri L. Lawver's Form 4 filing for Altimmune, Inc. (ALT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 May 2026, 16:23.

Change

Previous filing in this sequence was filed on 12 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001960596 Primary reporting owner

Lawver Teri L

Relationship: Director
Address: 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG
Signature: /s/ Gregory Weaver, as Attorney-in-Fact
Signature date: 01 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALT transaction Derivative

Stock Options (option to buy)

Award

Transaction value
Shares: +48,800
Change %
Price: $0.000000^*
Shares after: 48,800
Date: 01 May 2026
Ownership: Direct
Underlying class: Common Stock, par value $0.0001
Underlying amount: 48,800
Exercise price: $2.82
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options were granted pursuant to the Company's non-employee director compensation policy.

Footnote F2

The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.